(2010) in Journal of Investigative Dermatology tested GHK-Cu on 30 participants with aged skin
In a randomized, double-blind, placebo-controlled, phase IIb trial, the addition of sorafenib to capecitabine showed higher toxicity and no improvement in OS in patients with locally advanced or metastatic HER2-negative breast cancer ( p = 0.02) (Schwartzberg et al., 2013)
If you are in need of an IV with Glutathione and live in NYC, NJ or PA, we will come to you
This concern has not been studied longitudinally even in animal models the existing preclinical studies used relatively short treatment durations
Available from: Disclaimer : The information provided here is for educational/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition
When can results be expected in studies